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Abstract
Background: Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT
is ‘life expectancy > 3 months’, however the 90 day mortality (90DM) and overall survival (OS) of patients with
advanced solid malignancies are difficult to predict.
Methods: We analyzed 233 patients who were enrolled in PIT at Princess Margaret Hospital. We assessed the
relationship between 17 clinical characteristics and 90DM using univariate and multivariate logistic regression
analyses to create a risk score (PMHI). We also applied the Royal Marsden Hospital risk score (RMI), which consists
of 3 markers (albumin < 35g/L, > 2 metastatic sites, LDH > ULN).
Results: Median age was 57 years (range 21-88). The 90DM rate was 14%; median OS was 320 days. Predictors of
90DM were albumin < 35g/L (OR = 8.2, p = 0.01), > 2 metastatic sites (OR = 2.6, p = 0.02), and ECOG > 0 (OR =
6.3, p = 0.001); all 3 factors constitute the PMHI. To predict 90DM, the PMHI performed better than the RMI (AUC =
0.78 vs 0.69). To predict OS, the RMI performed slightly better (RMI ≥ 2, HR = 2.2, p = 0.002 vs PMHI ≥ 2, HR = 1.6,
p = 0.05).
Conclusions: To predict 90DM, the PMHI is helpful. To predict OS, risk models should include ECOG > 0, > 2
metastatic sites, and LDH > ULN. Prospective validation of the PMHI is warranted.
Background
The primary objectives of phase I trials (PIT) are to define
the toxicity profile of a new drug and to determine the
dose for further evaluation in phase II trials. Patients
enrolled in PIT are therefore placed at risk of toxicity, in
exchange for an undefined and limited clinical benefit.
Furthermore, patients who are considered for PIT may be
regarded as vulnerable because their physical condition
may be deteriorating due to advanced malignancy for
which no standard treatment options exist.
Selection of appropriate patients for entry onto PIT is
therefore critical for patient safety and to achieve study
aims. Eligibility criteria are used to minimize risk in
study participants and avoid factors that might interfere
with determining causality of adverse events. Typical
study entry criteria include reasonable performance sta-
tus, adequate organ functions and an anticipated life
expectancy of greater than 3 months. Retrospective
reviews by large phase I groups have demonstrated that
approximately 25% to 33% of patients do not meet the
necessary eligibility criteria at screening [1,2]. In addition,
up to 20% of patients die within the first 90 days of PIT
entry [3-5]. These early deaths on study are usually
attributed to disease progression, as contemporary PIT
are safe with a toxic death rate of around 0.5% [3,6-9].
Therefore, the current eligibility process to screen
patients may be inadequate, and an objective and repro-
ducible tool is needed to improve patient selection.
To address this need, several single-center, retrospec-
tive studies were performed to identify the predictors of
survival in patients on PIT [3-6,8-10]. The most recent
effort has been the development of a prognostic score to
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predict survival of patients treated on PIT, [3,4] which
was prospectively validated at the Royal Marsden Hospi-
tal in the United Kingdom [11]. Derivation of the score
was based on a retrospective study of 212 patients trea-
ted on PIT at the Royal Marsden Hospital between 2005
to 2006, which revealed in multivariate analysis that the
following items were significant independent covariates
for poor overall survival (OS): elevated LDH, low albu-
min and more than 2 sites of metastases [3]. The 3-
point prognostic score consisted of normal LDH versus
LDH > ULN (score = 0 versus +1), albumin ≥ 35 g/L
versus albumin < 35 g/L (score = 0 versus +1), and sites
of metastasis ≤ 2 versus > 2 (score = 0 versus +1). In
the retrospective study, nearly 90% of patients who died
within the first 90 days of study treatment had a risk
score of 2 or 3. The authors prospectively validated the
prognostic score at the same institution in 78 patients
treated in 19 PIT from March 2007 to June 2007 [11].
A significant difference in median survival was again
observed for patients in the good-prognosis group (risk
score 0 to 1, 33 weeks; 95% CI 24-42 weeks) compared
to the poor-prognosis group (risk score 2 to 3, 15.7
weeks; 95% CI 11-21 weeks), and thus the prognostic
score was an independent marker for OS (HR = 1.4; p =
0.037; 95% CI 1.02-1.9). The Royal Marsden Hospital
Index (RMI) has been validated at other centers in
Europe, [12] however the utility of the RMI in North
America is unknown.
We performed a retrospective analysis of patients
enrolled in PIT at the Princess Margaret Hospital
(PMH) over a period of 3.5 years. The goals of the study
were: (1) to identify predictors of 90DM in our cohort;
(2) to identify predictors of OS; (3) to validate the RMI
in a retrospective cohort of patients treated in our insti-
tution; and (4) to compare the performance of RMI to
that of our index (PMHI) in our cohort.
Methods
Patients were selected from the PMH Phase I Trials
Database, a registry of all patients enrolled on solid
tumor PIT at PMH, and included 271 consecutively
treated patients who had received at least one dose of
treatment, from 1 January 2006 to 1 July 2009. Patient
characteristics and vital status were obtained from the
PMH Phase I Trials Database, individual patient charts,
the PMH Cancer Registry and the Ontario Cancer Reg-
istry following approval from the University Health Net-
work Research Ethics Board, the PMH Cancer Registry
Database Access Committee and Cancer Care Ontario.
Statistical Methods
Descriptive statistics were used to summarize the study
cohort. All baseline characteristics were examined in
univariate analysis as predictors for 90DM and OS using
logistic regression and Cox proportional hazards model
respectively. Only those which were significant at the
0.10 (two-sided) level in the univariate analysis were
entered into the exploratory multivariate analysis, and
variables that remained significant at 0.05 (two-sided)
level in the multivariate analysis were considered signifi-
cant prognostic factors. For each individual, the RMI
score was also derived from the sum of the three compo-
nents used in the prognostic model established by the
Royal Marsden Hospital [3]. Patients were subcategorized
into two groups for the RMI: total score of 0 to 1 (good
risk group), and 2 to 3 (poor risk group). The Kaplan-
Meier method was used to estimate OS and the log-rank
test was used to compare survival curves. The receiver
operating characteristic curve was used to measure the
discrimination of 90DM by different prognostic indices.
The overall concordance index (C index) was used to
measure the discrimination ability for the survival analy-
sis models generated by the PMHI and RMI, with a value
of 0.5 having no discriminative ability and a score of 1.0
having perfect discriminative ability [13]. Statistical ana-




For the analysis of 90DM, we excluded 38 patients (11%)
from the cohort of 271 patients enrolled on PIT for the
following reasons: primary diagnosis of hematological
malignancies (n = 22) and missing data (90DM (n = 5),
performance status (n = 10), number of metastatic sites
(n = 1)). The baseline patient characteristics of the
remaining 233 patients are presented in Table 1. Median
age was 57 years (range: 21-88); 53% were male; the
majority had an Eastern Cooperative Oncology Group
(ECOG) performance status of 1 (52%); and the median
number of previous treatments was 2 (range: 0-14). A
variety of cancers were represented; the most common
was gastrointestinal origin (46%). Overall, 59% had 1 to 2
sites of metastases (median 3, range: 1-4 sites). The most
common sites of metastasis were the lung (55%), liver
(52%) and bone (17%). The majority of patients were
treated with a combination of molecularly targeted and
cytotoxic chemotherapeutic agents (58%); 38% were trea-
ted with molecularly targeted agents alone. Baseline bio-
chemistry revealed a low albumin (albumin < 35 g/L) in
3% of patients, and elevated LDH (LDH > ULN) in 39%
of patients. In terms of blood counts based on conven-
tional laboratory thresholds, hemoglobin of less than
12 g/dL, white blood count of more than 10.5 × 109/L
and platelet count of more than 400 × 109/L were present
in 39%, 13% and 12% of patients, respectively.
Chau et al. BMC Cancer 2011, 11:426
http://www.biomedcentral.com/1471-2407/11/426
Page 2 of 10
Patient outcomes: Early mortality, overall survival, and
response
Patient outcomes are described in Table 2. The 90DM in
our cohort was 14%. The median survival was 320 days
(range: 270-365 days) with a median follow-up time of
224 days (range: 23-1345 days). There were no reported
toxic deaths. Of the 233 patients, 196 (84%) were evalu-
able for objective response by Response Evaluation
Criteria in Solid Tumors (RECIST) [14]. The best overall
response by RECIST was partial response (PR) in 17
patients (9%), stable disease (SD) in 92 patients (47%),
and progressive disease (PD) in 87 patients (44%). The
clinical benefit rate (PR + SD) was 56% (109 patients). Of
those who achieved SD, the majority had a SD duration
of 3-6 months (54%) and about one quarter had SD for
over 6 months duration (23%).
Table 1 Baseline patient characteristics, n = 233
Characteristic Number % Median (range)
Gender Male 124 53
Age Median (range) 57 (21-88)
Performance status ECOG 0 105 45
ECOG 1 122 52
ECOG 2 6 3
No. of prior treatments 2 (0-14)
0-2 135 58
≥ 3 98 42
Primary tumor site Gastrointestinal 108 46
Thoracic, Head & Neck 58 25
Breast & Gynecological 40 17
Urologic: Sarcoma: Other 9: 5: 13 4:2:6
Type of trial Targeted agent alone 89 38.2
Cytotoxic agent alone 8 3.4
Combined 136 58.4
No. of metastatic sites 3 (1-4)
Locoregional disease* 20 9
1-2 sites 138 59
> 2 sites 75 32
Site of metastasis Liver 121 52
Lung 129 55
Bone 39 17
Baseline albumin 41 g/L (28-48 g/L)
< 35 g/L 8 3
≥ 35 g/L 225 97
Baseline LDH 224 U/L (93-3132 U/L)
Normal LDH 142 61
Elevated LDH > ULN 91 39
Baseline hemoglobin 12.5 g/dL (8.2-17.1 g/dL)
< 12 g/dL 90 39
≥ 12 g/dL 143 61
Baseline WBC 7 × 109/L (2.3-20.7 × 109/L)
≤ 10.5 × 109/L 203 87
> 10.5 × 109/L 30 13
Baseline platelets 264 × 109/L (106-832 × 109/L)
≤ 400 × 109/L 204 88
> 400 × 109/L 29 12
*Patients with locoregional disease were included as ≤ 2 metastatic sites in the analysis.
Abbreviations: No. = number; LDH = lactate dehydrogenase; WBC = white blood cells; ULN = upper limit of normal.
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Baseline predictors of 90-day mortality
The results of the univariate and multivariate analyses to
investigate predictors of 90DM are shown in Table 3. In
multivariate analysis, we found that albumin < 35g/L
(p = 0.008), > 2 metastatic sites (p = 0.02) and ECOG >
0 (p = 0.001) were significantly associated with 90DM in
our cohort. Using these 3 variables, a risk score was
constructed and evaluated (PMHI). One point was
assigned to each of the 3 variables. For PMHI score of
0-1, the 90DM rate was 7%, whereas a score of 2-3 was
associated with a 90DM rate of 37%.
We then evaluated the RMI developed by Arkenau
et al. [11], which consisted of albumin < 35 g/L, > 2
metastatic sites and elevated LDH. When applied to our
cohort, univariate and multivariate analyses demon-
strated that albumin and > 2 metastatic sites were sig-
nificant predictors of 90DM; albumin < 35 g/L (OR 8.13
95% CI 1.72-38.37, p = 0.008) and > 2 metastatic sites
(OR 2.32, 95% CI 1.02-5.28, p = 0.05). However, LDH
was not a significant predictor of 90DM in our cohort
(OR 1.58, 95% CI 0.69-3.60, p = 0.28). When RMI was
applied to our cohort, the 90DM rates were 11% for a
score of 0-1 and 29% for a score of 2-3, respectively.
Finally, we compared the test characteristics of the
PMHI and RMI in predicting 90DM using a dichotomized
score (0-1 vs 2-3) (Table 4). A PMHI score of 2-3 had an
Table 2 90 day mortality, overall survival and response data of entire cohort
Outcome Number % Median (days) 95% CI (days)
90 day mortality Alive ≥ 90 days 200 86
Alive < 90 days 33 14
Overall survival 320 270-365
Response by RECIST Partial Response 17/196 9
Stable Disease 92/196 47
Progressive Disease 87/196 44
Stable disease duration 0-3 months 20/86 23
3-6 months 46/86 54
> 6 months 20/86 23
Stable disease duration 1-2 cycles 13/90 15
3-4 cycles 23/90 26
5-6 cycles 29/90 32
> 6 cycles 25/90 27
Abbreviations: RECIST = Response Evaluation Criteria In Solid Tumors; CI = confidence interval.
Table 3 Univariate and multivariate predictors of 90 day mortality
Univariate model Multivariable model (stepwise)
Odds Ratios 95% CI p-value Odds Ratios 95% CI p-value
Male 1.42 0.67-3.01 0.36
Age ≥ 65 years old 0.54 0.21-1.38 0.21
Albumin < 35 g/L 11.73 2.66-51.78 0.01 8.24 1.75-38.81 0.008
LDH > ULN 1.81 0.86-3.79 0.12
Metastatic sites > 2 3.01 1.42-6.38 0.01 2.57 1.15-5.72 0.02
ECOG Performance Status > 0 7.40 2.51-21.81 0.01 6.23 2.06-18.83 0.001
Hemoglobin < 12 g/dL 2.47 1.167-5.21 0.02
WBC > 10.5 × 109/L 2.59 1.04-6.44 0.04
Platelets > 400 × 109/L 0.97 0.31-2.98 0.95
Lymphocytes < 0.7 × 109/L 2.21 0.94-5.23 0.07
Lung metastases 2.04 0.92-4.51 0.08
Liver metastases 2.04 0.94-4.43 0.07
Bone metastases 1.41 0.57-3.53 0.46
Brain metastases 6.22 0.38-101.94 0.22
Lymph node metastases 2.16 1.02-4.54 0.04
Peritoneal metastases 0.76 0.28-2.10 0.60
Prior treatments ≥ 3 0.76 0.35-1.64 0.48
Abbreviations: LDH = lactate dehydrogenase; ULN = upper limit of normal; ECOG = Eastern Cooperative Oncology Group; WBC = white blood cells; CI =
confidence interval.
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OR of 7.24 (95% CI 2.91-18.02), p < 0.0001. A RMI score
of 2-3 had an OR of 1.08 (95% CI 0.41-2.89), p = 0.88).
The sensitivity of the PMHI for predicting 90DM was 61%
with a specificity of 83%. The sensitivity of the RMI for
predicting 90DM was 36% with a specificity of 85%. The
area under the curve was significantly greater for the
PMHI (0.782) compared with the RMI (0.696, 95% CI
0.597-0.794, p = 0.02), or with other indices such as those
published by Penel et al. [9] (0.612, 95% CI 0.515-0.709,
p = 0.001) and Bachelot et al. [6] (0.582, 95% CI 0.509-
0.654, p = 0.0002) (Figure 1).
Baseline predictors of overall survival
The results of the univariate and multivariate analyses to
investigate predictors of OS are shown in Table 5. In
multivariate analysis, we found that high LDH (p =
0.001), > 2 metastatic sites (p = 0.004) and ECOG > 0
(p = 0.05) were significantly associated with OS in our
cohort. When the PMHI was applied to predict OS, num-
ber of metastatic sites was the only significant predictor
(Table 6). By contrast, when using the RMI, both LDH
and number of metastatic sites were significant predic-
tors of OS (Table 6). The C index for the PMHI is 0.89
(95% CI 0.76-0.98). The C index for the RMI is 0.87 (95%
CI 0.73-0.96). The median OS according to PMHI and
RMI risk score is presented in Table 7.
Overall, the RMI performed slightly better than the
PMHI in predicting OS. A RMI score of 2-3 had a HR of
2.18 (95% CI 1.33-3.58, p = 0.002), while a PMHI score
of 2-3 had a HR of 1.58 (95% CI 1.01-2.47, p = 0.05). The
Kaplan-Meier survival plot by PMHI score category (0-1
vs 2-3) is illustrated in Figure 2. Patients with PMHI
score of 0-1 had a better OS (median OS = 250 days, 95%
CI 299-414 days) compared to those with PMHI scores
of 2-3 (median OS = 237 days, 95% CI 87-270 days) (log-
rank test, p < 0.0001). The survival plot by RMI score
category (0-1 vs 2-3) is illustrated in Figure 3. Patients
with RMI score of 0-1 had a better OS (median OS = 353
days, 95% CI 315-445 days) than those with RMI scores
of 2-3 (median OS = 137 days, 95% CI 104-223 days)
(log-rank test p < 0.0001).
Overall survival is correlated with tumor response
OS was associated with best response by RECIST.
Patients with PR had a median OS of 603 days (95% CI
433-756), patients with SD had a median OS of 501 days
(95% CI 365-838), and patients with PD had a median
OS of 158 days (95% CI 131-205) (log-rank p < 0.0001).
Patients with a longer duration of SD had a significantly
longer OS. Patients with SD for more than 6 months had
a median OS of 561 days (95% CI 412-not reached),
patients with SD for 3-6 months had a median OS of 414
days (95% CI 346-not reached) and patients with SD for
less than 3 months had a median OS of 185 days (95% CI
135-538) (log-rank p < 0.01). Patients with SD for 3
cycles or more had improved OS (median OS = 538 days,
95% CI 400-719) compared to patients with PD or SD of
1-2 cycles (median OS = 171 days, 95% CI 136-204) (log-
rank, p < 0.0001). In addition, OS appeared to be similar
for patients with SD for 1-2 cycles (median OS = 171
days, 95% CI 78-not reached) and patients with PD (med-
ian OS = 158 days, 95% CI 131-205) (log-rank, p = 0.25).
Discussion
Selection of patients in oncology PIT remains controver-
sial with often unclear benefit at the cost of potential
patient risk [15-17]. Consistent with other studies,
[3,4,6-8,11,18] we found a 90-day mortality rate of 14%,
while treatment-related deaths were extremely rare (0% in
our study). This suggests that early mortality is largely due
to cancer progression and it has been proposed that the
current patient selection process may be improved with
the use of objective selection criteria. We showed that
albumin, number of metastatic sites and performance sta-
tus are independent predictors of 90DM.
The PMHI was superior in predicting 90DM in our
patient population, when compared to other risk indices
designed to predict mortality in oncology PIT patients
[3-6,9]. One explanation may be that a model generated
from a single institution’s data set will likely perform best
in the same institution, compared to an alternative model
generated from an external data set. Secondly, the PMHI
is derived from predictors of 90DM, which is a clinically
Table 4 Comparison of test characteristics for predicting 90 day mortality: PMHI vs. RMI using a dichotomized score
(0-1 vs 2-3)
Test Characteristic PMHI RMI
Score ≥ 2 in multivariate analysis OR 7.24 (95% CI: 2.91-18.02), p < 0.0001 OR 1.08 (95% CI: 0.41-2.89), p = 0.88
Sensitivity 61% 36%
Specificity 83% 85%
Positive likelihood ratio 3.57 2.42
False positive rate 14.6% 12.9%
False negative rate 5.6% 9.0%
Area under curve (AUC) 0.782 0.696
Abbreviations: PMHI = Princess Margaret Hospital Index; RMI = Royal Marsden Hospital Index; OR = odds ratio.
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relevant and distinct endpoint compared to OS. Whereas,
the RMI, which was derived from predictors of OS was
superior in predicting OS in our cohort. Thirdly, other
risk indices designed to predict 90DM are based on het-
erogeneous patient populations, including those treated
over 10 years ago. Bachelot et al. [6] evaluated 154
patients enrolled in phase I trials from 1986 to 1993 and
identified two independent risk factors for 90DM (LDH >
600 IU and ECOG > 1). Penel et al. [9] analyzed 148
patients who were screened for phase I trial entry from
1997 to 2002 and identified albumin < 38 g/L and lym-
phocyte count < 700/mm3 to be independent predictors
of 90DM. The same authors validated these predictors in
a cohort of 128 patients treated with cytotoxic agents
 
Figure 1 Receiver operator curve for comparison of PMHI, RMI, Penel index and Bachelot index for predicting 90 day mortality.
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from 1986 to 1993 at a separate center [5]. To date, no
risk index has been prospectively validated to predict
90DM.
In predicting OS, the PMHI performed well but was
slightly inferior to the RMI. The PMHI and RMI are
similar in that they both include albumin < 35 g/L and
number of metastatic sites. Compared to the RMI, the
PMHI substitutes ECOG > 0 for LDH. Our findings may
suggest that ECOG is an important predictor of early
death within 3 months, whereas LDH, which reflects
overall tumor burden, may be a better predictor of total
disease burden and OS. The high proportion of patients
with a good performance status in our study (ECOG 0 =
45%) compared to the initial study by Arkenau et al. [3]
(ECOG 0 = 28%) may have contributed to the impor-
tance of ECOG in our cohort. In predicting OS in our
cohort, both risk indices were likely weakened by the
inclusion of albumin < 35 g/L, which was not a signifi-
cant predictor in multivariate analysis of OS. Albumin <
35 g/L, a marker of nutritional status, was present in only
3% of patients in our cohort, and therefore likely too rare
to demonstrate an association with survival.
In keeping with other studies, [6,8,9,11,12,19] we con-
firmed that other baseline characteristics such as tumor
Table 5 Univariate and multivariate predictors of overall survival
Univariate model Multivariable model (stepwise)
Variables Median OS (days) 95% CI p-value (Log-rank) Hazard ratio 95% CI p-value
Gender Female 365 276-501 0.05
Male 270 204-346
Age < 65 years 325 271-400 0.81
≥ 65 years 297 210-398
Albumin ≥ 35 g/L 325 271-365 0.02
< 35 g/L 54 42-408
LDH Normal 366 320-501 0.001
Elevated 210 147-276 1.75 1.24-2.46 0.001
No. of metastatic sites ≤ 2 358 299-446 0.0001
> 2 210 136-290 1.68 1.18-2.40 0.004
ECOG Performance Status 0 366 302-464 0.02
> 0 270 158-325 1.42 1.00-1.99 0.05
Hemoglobin ≥ 12 g/dL 350 273-412 0.09
< 12 g/dL 276 185-346
WBC ≤ 10.5 × 109/L 345 276-398 0.07
> 10.5 × 109/L 236 103-352
Platelets ≤ 400 × 109/L 329 273-398 0.23
> 400 × 109/L 261 137-352
Lymphocytes ≥ 0.7 × 109/L 346 290-400 0.04
< 0.7 × 109/L 166 99-315
Lung metastases No 338 271-414 0.58
Yes 302 223-365
Liver metastases No 366 297-501 0.01
Yes 250 191-329
Bone metastases No 329 276-365 0.32
Yes 261 135-433
Brain No 320 270-358 0.47
Yes 269.5 40-499
Peritoneal Mets No 325 250-365 0.99
Yes 315 257-474
No. of prior treatments < 3 302 266-365 0.76
≥ 3 320 227-400
Abbreviations: LDH = lactate dehydrogenase; No. = number; ECOG = Eastern Cooperative Oncology Group; WBC = white blood cells; OS = overall survival; CI =
confidence interval
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type, number of prior therapies and older age, were not
significant predictors of early mortality or OS. This con-
sistent finding affirms that patients should not be
excluded from enrolment in oncology PIT on the basis of
age, multiple lines of prior therapy or primary tumor his-
tology alone.
Another interesting finding in our analysis is that
patients with prolonged SD > 3 cycles had an OS similar
to that of patients with PR, and a much better OS than
patients with SD of 1-2 cycles and PD. This supports the
notion of potential therapeutic benefit with prolonged
disease control on contemporary PITs. Indeed, disease
control (CR, PR and SD) has been associated with
increased survival in patients on PIT [8]. Disease control
may be particularly important when evaluating new
molecularly targeted agents that may exert greater cyto-
static rather than cytotoxic effects. Our study cohort
reflects a contemporary PIT patient population treated
on modern and often complex phase I protocols. Over
95% of our patients were treated with novel molecularly
targeted agents alone or in combination with cytotoxic
agents. The median survival in our cohort of 10.7 months
is longer than that previously published by several other
PIT groups (5.7-9.0 months) [8-11]. The clinical benefit
rate in our cohort of 56% is consistent with that reported
by other recent studies (45-55%) [3,7,8,20].
There are inherent limitations in this type of analysis.
Firstly, the analysis was conducted retrospectively.
Although the PMHI was able to identify patients with a
greater risk of early mortality in a retrospective cohort,
we recognize that our results need to be validated pro-
spectively. Ideally, prospective evaluation of the PMHI
should also occur in patients who are being screened for
PITs in order to assist with patient decision-making prior
to enrolment. Secondly, the study was performed at a sin-
gle center in North America and therefore the PMHI
should be validated across different centers, including
those outside of North America. Furthermore, we evalu-
ated patients enrolled in 30 different phase I trials.
Although patient heterogeneity may be a confounder in
our analysis, it is important to note that tumor histology
was not a significant predictor of early mortality in
patients enrolled on PIT in our study and previous stu-
dies [4,6,9]. Lastly, the findings of PMHI on 90DM
should be viewed as exploratory. Given the relatively few
number of events of 90DM to the number of predictors,
potential bias and overfitting of data exist. A recent simu-
lation study suggests that the commonly used 10:1 rule
for the number of predictors per events may be overly
stringent and can be relaxed [21]. Therefore, our findings
will require careful internal and external validation to
confirm validity. Nevertheless, our study cohort repre-
sents the largest cohort of PIT patients in North America
analyzed for predictors of 90DM.
The PMHI and RMI are useful tools that can assist
with patient selection for oncology P1T. In our cohort of
unselected patients there were 33 deaths within 90 days
of study entry (14%). Limiting patient enrolment to only
those with PMHI score 0-1, would result in a reduction
of 90DM from 14% to 5.6%. If enrolment was limited to
Table 6 Variables associated with overall survival in multivariate regression analyses: PMHI vs. RMI
Overall Survival Predictors Hazard Ratio 95% CI p-value
PMHI
Albumin < 35 g/L 1.99 0.86-4.58 0.11
> 2 metastatic sites 1.79 1.26-2.53 0.01
ECOG Performance Status > 0 1.36 0.96-1.91 0.08
RMI
Albumin < 35 g/L 1.94 0.84-4.48 0.12
> 2 metastatic sites 1.74 1.23-2.48 0.01
LDH > ULN 1.69 1.20-2.38 0.01
Abbreviations: PMHI = Princess Margaret Hospital Index; RMI = Royal Marsden Hospital Index; ECOG = Eastern Cooperative Oncology Group; LDH = lactate
dehydrogenase; ULN = upper limit of normal; CI = confidence interval.
Table 7 Overall survival according to risk score: Comparison of PMHI and RMI in predicting overall survival
Risk Score PMHI RMI
No. Dead Censored Median OS (95% CI) in days No. Dead Censored Median OS (95% CI) in days
Score 0 79 41 38 412 (329-515) 104 55 49 400 (325-561)
Score 1 100 58 42 320 (239-365) 87 53 34 315 (205-366)
Score 2 51 40 11 154 (87-270) 39 31 8 137 (104-223)
Score 3 3 3 0 54 (54-408)* 3 3 0 54 (54-408)*
*too few patients in this stratum to provide a stable 95% CI.
Abbreviations: PMHI = Princess Margaret Hospital Index; RMI = Royal Marsden Hospital Index; No. = number; OS = overall survival; CI = confidence interval
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patients with RMI score 0-1, the 90DM would be 9%.
However, neither the PMHI or RMI alone is adequate to
exclude patients from PIT entry due to the low positive
predictive value which would restrict access for some
patients who may have benefited. By excluding patients
with a PMHI score of 2-3, we would wrongly exclude 34
patients (15%) from study entry, but prevent 20 early
deaths on study. Whereas, by excluding patients with a
RMI score of 2-3, we would wrongly exclude 30 patients
(13%), but prevent 12 early deaths on study.
Conclusions
Our findings demonstrate that a simple objective risk
score consisting of albumin, number of metastatic sites
and performance status, can be useful to assist in identi-
fying patients enrolled on PIT who are at a greater risk of
early death. This risk score needs to be validated pro-
spectively in other centers.
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